Overview
Treacher Collins syndrome (TCS), also known as mandibulofacial dysostosis or Franceschetti-Zwahlen-Klein syndrome, is a rare genetic disorder affecting the development of bones and other tissues of the face. It is caused by mutations in the TCOF1 gene (most commonly, accounting for approximately 78-93% of cases), POLR1C gene, or POLR1D gene, all of which play critical roles in ribosomal RNA biogenesis and craniofacial development during embryogenesis. The condition primarily affects structures derived from the first and second pharyngeal arches. Key clinical features include bilateral and symmetric downward-slanting palpebral fissures (eye openings), coloboma (notching) of the lower eyelids with sparse or absent eyelashes on the lower lids, hypoplasia (underdevelopment) of the zygomatic bones and mandible (giving the face a characteristic flattened appearance), malformation or absence of the external ears (microtia or anotia), and conductive hearing loss due to abnormalities of the middle ear ossicles and external auditory canals. Cleft palate occurs in approximately 30% of affected individuals. The severity of the condition is highly variable, even within the same family, ranging from barely noticeable facial differences to severe craniofacial anomalies that can cause life-threatening airway compromise in newborns. There is currently no cure for Treacher Collins syndrome, and management is multidisciplinary and symptom-based. Treatment typically involves a coordinated team including craniofacial surgeons, otolaryngologists, audiologists, speech therapists, orthodontists, and psychologists. Airway management is the first priority in severely affected neonates, sometimes requiring tracheostomy. Hearing aids or bone-anchored hearing devices are used to address conductive hearing loss. Surgical reconstruction of the facial bones, ears, and eyelids is often performed in stages throughout childhood and adolescence. Early intervention with speech therapy and educational support is important to optimize developmental outcomes. Genetic counseling is recommended for affected individuals and their families.
Clinical phenotype terms— hover any for plain English:
Variable
Can be inherited in different ways depending on the underlying gene
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Treacher-Collins syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Treacher-Collins syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Treacher-Collins syndrome.
Community
No community posts yet. Be the first to share your experience with Treacher-Collins syndrome.
Start the conversation →Latest news about Treacher-Collins syndrome
No recent news articles for Treacher-Collins syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Treacher-Collins syndrome
What is Treacher-Collins syndrome?
Treacher Collins syndrome (TCS), also known as mandibulofacial dysostosis or Franceschetti-Zwahlen-Klein syndrome, is a rare genetic disorder affecting the development of bones and other tissues of the face. It is caused by mutations in the TCOF1 gene (most commonly, accounting for approximately 78-93% of cases), POLR1C gene, or POLR1D gene, all of which play critical roles in ribosomal RNA biogenesis and craniofacial development during embryogenesis. The condition primarily affects structures derived from the first and second pharyngeal arches. Key clinical features include bilateral and sym
At what age does Treacher-Collins syndrome typically begin?
Typical onset of Treacher-Collins syndrome is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Treacher-Collins syndrome?
11 specialists and care centers treating Treacher-Collins syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.